Studies showing that hormone replacement therapy can raise the risk of heart disease, cancer and blood clots have knocked U.S. prescriptions for the drugs back to where they were nine years ago, according to a report in this week's issue of the Journal of the American Medical Association.
This suggests that doctors "may rapidly abandon well-established therapies when studies demonstrate harm" and that "patients also played a major role" in the reversal, Stanford University School of Medicine researchers noted.
The authors found that the number of hormone therapy prescriptions rose to 90 million in 1999 from 58 million in 1995 and remained stable through June 2002. Estrogen/progestin combinations, primarily Wyeth's Prempro, accounted for most of the growth.
Study findings released starting in July 2002 triggered an avalanche of bad news about the therapy, and a sharp drop in prescriptions followed.
If prescription rates seen through July 2003 continue, the report said, there were probably 57 million written last year, close to the rate in 1995.
The U.S. Food and Drug Administration recommends that post-menopausal women who take hormone therapy for hot flashes or vaginal dryness use the lowest possible dose for the shortest possible time.
SOURCE: Journal of the American Medical Association, January 7, 2003.
Ultimi Articoli
Strapazzami di coccole Topo Gigio il Musical: una fiaba che parla al cuore
Goldoni al Teatro San Babila di Milano con La Locandiera
Ceresio in Giallo chiude con 637 opere: giallo, thriller e noir dall'Italia all'estero
Milano celebra Leonardo — al Castello Sforzesco tre iniziative speciali per le Olimpiadi 2026
Trasporto ferroviario lombardo: 780.000 corse e 205 milioni di passeggeri nel 2025
Piazza Missori accoglie la Tenda Gialla – Tre giorni di volontariato under zero con i Ministri di Scientology
Neve in pianura tra venerdì 23 e domenica 25 gennaio — cosa è realmente atteso al Nord Italia
Se ne va Valentino, l'ultimo imperatore della moda mondiale
La mortalità per cancro cala in Europa – tassi in diminuzione nel 2026, ma persistono disparità